Evelo Biosciences, Inc.
EVLODelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001694665
Evelo Biosciences, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Nov 8, 2023; 29 institutions reported holding it in 13F filings for Q3 2023, worth $52.0M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Evelo Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Evelo Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bodmer Mark | CSO, President of R&D | 25,732 | Nov 8, 2023 | 0 |
| McHale Duncan | Chief Medical Officer | 16,984 | Nov 8, 2023 | 0 |
| Gill Simba | President & CEO | 17,758 | Nov 8, 2023 | 0 |
| Thorell Marella | Chief Financial Officer | 22,259 | Nov 8, 2023 | 0 |
| Afeyan Noubar | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Flagship Pioneering, LLC | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Flagship Ventures Fund IV, L.P. | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Flagship Ventures Fund IV General Partner LLC | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Nutritional Health LTP Fund General Partner LLC | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Nutritional Health LTP Fund, L.P. | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Flagship Pioneering Fund VII, L.P. | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Flagship Pioneering Fund VII General Partner LLC | 10% Owner | 3,931,685Indirect | Jul 13, 2023 | 0 |
| Moore Jeffrey R. | Director | – | Jul 12, 2023 | 0 |
| Reynolds Alexander C | Director | – | Jul 12, 2023 | 0 |
| Melas Kyriazi Theo | Director | – | Jun 12, 2023 | 0 |
| McHugh Julie | Director | – | Jun 12, 2023 | 0 |
| Rosiello Robert L. | Director | – | Jun 12, 2023 | 0 |
| Gutierrez-Ramos Jose-Carlos | Director | – | Jun 12, 2023 | 0 |
| Hohneker John | Director | – | Jun 12, 2023 | 0 |
| Andres Juan | Director | – | Jun 12, 2023 | 0 |
| McInnes Iain B. | Director | – | Jun 12, 2023 | 0 |
| Williams Tonya | Director | – | Jun 12, 2023 | 0 |
| Plinio Mark D. | Chief Commercial Officer | 3,750 | Feb 2, 2023 | 0 |
| Carriere Stephen J | Principal Accounting Officer | 203 | Jan 23, 2023 | 0 |
| Char Daniel | General Counsel | – | Oct 14, 2022 | 0 |
| Zung Jonathan B. | Chief Development Officer | – | Oct 14, 2022 | 0 |
| Epstein David R | Director | 93,932 | Jun 30, 2022 | 0 |
| Darzi Lord Ara | Director | 342,465 | Jun 13, 2022 | 0 |
| Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | 13,698,630Indirect | Jun 1, 2022 | 0 |
| Flagship Ventures Opportunities Fund I, L.P. | 10% Owner | 13,698,630Indirect | Jun 1, 2022 | 0 |
| Flagship Ventures Opportunities Fund I General Partner LLC | 10% Owner | 13,698,630Indirect | Jun 1, 2022 | 0 |
| Scavo Luca | CFO | – | Jan 21, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 8, 2023 (view filing)8:32 PM ET | Nov 8 | Same day | Bodmer MarkCSO, President of R&D | SSale | −3.16K | $0.33 | −$1.04K | −10.9%25.7K after | 10b5-1 |
| Nov 8, 2023 (view filing)8:32 PM ET | Nov 8 | Same day | McHale DuncanChief Medical Officer | SSale | −3.10K | $0.33 | −$1.02K | −15.4%17.0K after | 10b5-1 |
| Nov 8, 2023 (view filing)8:31 PM ET | Nov 8 | Same day | Gill SimbaPresident & CEO | SSale | −172 | $0.33 | −$56.76 | −1.0%17.8K after | 10b5-1 |
| Nov 8, 2023 (view filing)8:31 PM ET | Nov 8 | Same day | Thorell MarellaChief Financial Officer | SSale | −1.81K | $0.33 | −$597.63 | −7.5%22.3K after | 10b5-1 |
| Nov 3, 2023 (view filing)4:12 PM ET | Nov 2 | 1 day | Bodmer MarkCSO, President of R&D | SSale | −6.85K | $0.33 | −$2.26K | −23.5%22.3K after | 10b5-1 |
| Nov 3, 2023 (view filing)4:11 PM ET | Nov 2 | 1 day | McHale DuncanChief Medical Officer | SSale | −6.85K | $0.33 | −$2.26K | −33.5%13.6K after | 10b5-1 |
| Nov 3, 2023 (view filing)4:11 PM ET | Nov 2 | 1 day | Thorell MarellaChief Financial Officer | SSale | −4.00K | $0.33 | −$1.32K | −18.5%17.6K after | 10b5-1 |
| Sep 29, 2023 (view filing) | Sep 28 | 1 day | Gill SimbaPresident & CEO | SSale | −2.00K | $3.94 | −$7.86K | −10.6%16.8K after | 10b5-1 |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Bodmer MarkCSO, President of R&D | SSale | −3.13K | $9.51 | −$29.7K | −15.8%16.6K after | 10b5-1 |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Gill SimbaPresident & CEO | SSale | −342 | $9.51 | −$3.25K | −8.3%3.75K after | 10b5-1 |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | McHale DuncanChief Medical Officer | SSale | −3.43K | $9.51 | −$32.7K | −30.2%7.94K after | 10b5-1 |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Thorell MarellaChief Financial Officer | SSale | −2.00K | $9.51 | −$19.1K | −18.1%9.07K after | 10b5-1 |
| Jul 13, 2023 (view filing)5:15 PM ET | Jul 11 | 2 days | Afeyan Noubar and 7 others10% Owner | PPurchase | +5.41M | $2.31 | +$12.5M | New position3.93M after | 3 lots |
| Jun 12, 2023 (view filing)4:01 PM ET | May 23 | 20 daysLate | Bodmer MarkCSO, President of R&D | SSale | −22.6K | $0.1418 | −$3.20K | −7.9%262.6K after | 10b5-1 |
| May 10, 2023 (view filing)9:32 PM ET | May 8 | 2 days | McHale DuncanChief Medical Officer | SSale | −66.7K | $0.1255 | −$8.37K | −40.6%97.5K after | 10b5-1 |
| May 10, 2023 (view filing)9:31 PM ET | May 8 | 2 days | Bodmer MarkCSO, President of R&D | SSale | −68.0K | $0.1255 | −$8.54K | −19.3%285.1K after | 10b5-1 |
| May 10, 2023 (view filing)9:31 PM ET | May 8 | 2 days | Thorell MarellaChief Financial Officer | SSale | −38.5K | $0.1255 | −$4.84K | −29.6%91.5K after | 10b5-1 |
| May 10, 2023 (view filing)9:31 PM ET | May 8 | 2 days | Gill SimbaPresident & CEO | SSale | −3.54K | $0.1255 | −$443.89 | −5.7%58.5K after | 10b5-1 |
| Jan 23, 2023 (view filing) | Jan 23 | Same day | Carriere Stephen JPrincipal Accounting Officer | SSale | −151 | $1.06 | −$160.06 | −42.7%203 after | |
| Jun 1, 2022 (view filing)7:00 PM ET | May 27 | 5 days | Afeyan Noubar and 8 others10% Owner | PPurchase | +27.4M | $1.46 | +$40.0M | New position13.7M after | 5 lots |
| May 31, 2022 (view filing) | May 27 | 4 days | McHale DuncanChief Medical Officer | PPurchase | +34.2K | $1.46 | +$50.0K | New position34.2K after | |
| May 31, 2022 (view filing) | May 27 | 4 days | Darzi Lord AraDirector | PPurchase | +342.5K | $1.46 | +$500.0K | New position342.5K after | |
| May 31, 2022 (view filing) | May 27 | 4 days | Epstein David RDirector | PPurchase | +17.1K | $1.46 | +$25.0K | +25.6%84.1K after |